Literature DB >> 20545033

Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease.

Sarah Payton.   

Abstract

Entities:  

Year:  2010        PMID： 20545033     DOI： 10.1038/nrurol.2010.69

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Authors:  Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers
Journal:  Lancet       Date:  2010-04-14       Impact factor: 79.321
  1 in total
  5 in total

Review 1.  Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.

Authors:  Lucas J Brand; Scott M Dehm
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

Review 2.  Alternatively spliced androgen receptor variants.

Authors:  Scott M Dehm; Donald J Tindall
Journal:  Endocr Relat Cancer       Date:  2011-09-20       Impact factor: 5.678

3.  Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.

Authors:  Chengfei Liu; Yezi Zhu; Wei Lou; Yuanyuan Cui; Christopher P Evans; Allen C Gao
Journal:  Prostate       Date:  2013-10-16       Impact factor: 4.104

4.  NUMB suppression by miR-9-5P enhances CD44+ prostate cancer stem cell growth and metastasis.

Authors:  Xuan Wang; Jun Cai; Lei Zhao; Dejun Zhang; Guojie Xu; Jianli Hu; Tao Zhang; Min Jin
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

Review 5.  Trial Watch: DNA vaccines for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-04-01       Impact factor: 8.110
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.